CD274 and non-small cell lung carcinoma: Humanized monoclonal antibody IgG1 against PD-L1 was approved for the treatment of urothelial carcinoma, showing efficacy in maintenance therapy of unresectable NSCLC after chemotherapy (PACIFIC study).